title: High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21).
abstract: Seventeen patients affected by acute myeloid leukemia (AML) with t(8;21) were prospectively programmed to receive three courses of high-dose cytarabine (HDARA-C) as post-remission therapy. The median age was 39 years and in all cases t(8;21) was the only karyotypic abnormality. Complete remission (CR) was achieved in 14 out of 17 cases (82%) and, after first consolidation with NOVIA regimen (intermediate dose ARA-C plus mitoxantrone), all patients received the three planned courses of HDARA-C (3g/m(2) q12h on days 1, 3, 5). There were two documented infections, while all patients experienced fever of unknown origin (FUO). Nonhematological toxicity was mild. Thirteen out of 14 patients are in continuous CR after a median follow-up of 44 months. One patient relapsed at 16 months and, following CR2 achievement, underwent allogeneic transplantation; he died 3 months later while in CR from acute graft versus host disease (GVHD). Survival at 5 years is projected at 79%. Our data confirm the efficacy of repeated courses of HDARAC for patients with t(8;21) AML.
authors: Division of Hematology, Cardarelli Hospital, Naples, Italy.
authors: Salvatore
authors: S
authors: Palmieri
authors: Lucia
authors: L
authors: Sebastio
authors: Giuseppina
authors: G
authors: Mele
authors: Mario
authors: M
authors: Annunziata
authors: Silvana
authors: S
authors: Annunziata
authors: Carolina
authors: C
authors: Copia
authors: Assunta
authors: A
authors: Viola
authors: Mariacarla
authors: M
authors: De Simone
authors: Barbara
authors: B
authors: Pocali
authors: Ettore Mariano
authors: EM
authors: Schiavone
authors: Felicetto
authors: F
authors: Ferrara
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002891:Chromosomes, Human, Pair 21; D002898:Chromosomes, Human, Pair 8; D003561:Cytarabine / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016019:Survival Analysis; D014178:Translocation, Genetic; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine